- Home
- VELO vs ZNTL Comparison
VELO vs ZNTL Comparison
Compare VELO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VELO | ZNTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 134 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 289.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VELO | ZNTL |
|---|---|---|
| Price | $25.41 | $4.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $6.60 |
| AVG Volume (30 Days) | ★ 2.9M | 956.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.22 | N/A |
| Revenue Next Year | $50.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.87 | $1.13 |
| 52 Week High | $25.73 | $6.95 |
Technical Indicators
Market Signals| Indicator | VELO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 72.71 | 50.55 |
| Support Level | $12.06 | $3.75 |
| Resistance Level | N/A | $4.40 |
| Average True Range (ATR) | 2.69 | 0.30 |
| MACD | 0.89 | -0.04 |
| Stochastic Oscillator | 96.96 | 52.24 |
Price Performance
Historical ComparisonAbout VELO Velo3D Inc.
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.